Nontuberculous Mycobacterial Infection Market Report 2026
Download Free Sample Buy Now
Nontuberculous Mycobacterial Infection Market Global Report 2026 Market Report Infographic Image

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Nontuberculous Mycobacterial Infection Market Report 2026

Global Outlook – By Drug Class (Macrolides, Rifampin, Aminoglycoside, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Nontuberculous Mycobacterial Infection Market Overview

• Nontuberculous Mycobacterial Infection market size has reached to $14.96 billion in 2025

• Expected to grow to $21.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%

• Growth Driver: Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market

• Market Trend: Innovations In Boron-Based Antibiotics Enhance Treatment Efficacy And Address Drug-Resistant Nontuberculous Mycobacterial Infections

• North America was the largest region and fastest growing region.

What Is Covered Under Nontuberculous Mycobacterial Infection Market?

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.

The main classes of drugs for nontuberculous mycobacterial infection are macrolides, rifampin, aminoglycoside and others. Macrolides are a class of antibiotics that are commonly used to treat a variety of bacterial infections. They can be administered through oral, parenteral and other routes, which can be distributed by various channels such as hospital pharmacies, retail pharmacies and online pharmacies.

Nontuberculous Mycobacterial Infection Market Global Report 2026 Market Report bar graph

What Is The Nontuberculous Mycobacterial Infection Market Size and Share 2026?

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.96 billion in 2025 to $15.87 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to high incidence of pulmonary infections, limited effective therapies, delayed diagnosis of nontuberculous mycobacteria, reliance on conventional antibiotic regimens, low awareness among clinicians.

What Is The Nontuberculous Mycobacterial Infection Market Growth Forecast?

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $21.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rising adoption of macrolide and rifampin combination therapies, increasing availability of aminoglycosides, growth of personalized treatment approaches, expansion of hospital and specialty pharmacy networks, development of ai-enabled monitoring and diagnostic tools. Major trends in the forecast period include rising adoption of macrolide and rifampin therapies, increasing use of aminoglycoside-based treatments, growing implementation of combination drug regimens, expanding deployment of advanced diagnostic tools, advancing integration of ai-powered treatment monitoring.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Nontuberculous Mycobacterial Infection Market Segmentation

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Macrolides: Azithromycin, Clarithromycin, Erythromycin

2) By Rifampin: Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy

3) By Aminoglycoside: Amikacin, Streptomycin, Tobramycin

4) By Other Drug Classes: Fluoroquinolones, Ethambutol, Linezolid, Clofazimine

What Is The Driver Of The Nontuberculous Mycobacterial Infection Market?

The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the nontuberculous mycobacterial infection market going forward. Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent and often progressive lung airflow limitation. Nontuberculous mycobacterial (NTM) infections in patients with COPD are associated with a more significant decline in forced expiratory volume in one second (FEV1) and an increased exacerbation rate. COPD may weaken the immune system and damage the lung tissue, making it easier for NTM bacteria to infect the lungs. For instance, in September 2024, according to Public Health Scotland, a Scotland-based government health agency, in Scotland during 2022/23, the incidence of COPD, based on hospital admissions and death records, was 112.4 cases per 100,000 for females and 109.7 cases per 100,000 for males. Therefore, the rising prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of the nontuberculous mycobacterial infection industry.

Key Players In The Global Nontuberculous Mycobacterial Infection Market

Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.

Global Nontuberculous Mycobacterial Infection Market Trends and Insights

Major companies operating in the nontuberculous mycobacterial infection market are focusing on developing advanced solutions, such as boron-based antibiotics, to enhance treatment efficacy, overcome drug resistance, and improve patient outcomes. Boron-based antibiotics are small-molecule therapies designed to inhibit bacterial protein synthesis, offering potent and safer options for persistent infections. For instance, in September 2023, AN2 Therapeutics, a US-based biopharmaceutical company, initiated enrolment in the Phase 3 part of its pivotal Phase 2/3 clinical trial for epetraborole in treatment-refractory Mycobacterium avium complex lung disease after completing Phase 2 enrolments. Designed for oral administration, epetraborole demonstrated potential in preclinical studies to treat Mycobacterium abscessus infections, aiming to reduce treatment duration, improve tolerability, and address unmet medical needs in rare and serious infectious lung diseases, thereby supporting enhanced patient outcomes and disease management.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market?

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, partnered with TB Alliance. This partnership aims to develop telacebec, a drug to treat tuberculosis and other nontuberculous mycobacteria (NTM) infections. TB Alliance will be granted the only global license for Telacebec through the agreement. This indicates that the TB Alliance will have the authority to continue working on the medicine and market it internationally. TB Alliance is a South Africa-based non-profit organization that develops and delivers economic TB medications.

Regional Outlook

North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nontuberculous Mycobacterial Infection Market?

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nontuberculous Mycobacterial Infection Market Report 2026?

The nontuberculous mycobacterial infection market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Nontuberculous Mycobacterial Infection Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $15.87 billion
Revenue Forecast In 2035 $21.01 billion
Growth Rate CAGR of 6.1% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drug Class, Route Of Administration, Distribution Channel
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Nontuberculous Mycobacterial Infection Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Nontuberculous Mycobacterial Infection Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Nontuberculous Mycobacterial Infection Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Nontuberculous Mycobacterial Infection Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.1.4 Digitalization, Cloud, Big Data & Cybersecurity

4.1.5 Industry 4.0 & Intelligent Manufacturing

4.2. Major Trends

4.2.1 Rising Adoption Of Macrolide And Rifampin Therapies

4.2.2 Increasing Use Of Aminoglycoside-Based Treatments

4.2.3 Growing Implementation Of Combination Drug Regimens

4.2.4 Expanding Deployment Of Advanced Diagnostic Tools

4.2.5 Advancing Integration Of Ai-Powered Treatment Monitoring

5. Nontuberculous Mycobacterial Infection Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Ambulatory Care Centers

5.4 Diagnostic Laboratories

5.5 Pharmacy Chains

6. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nontuberculous Mycobacterial Infection Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Nontuberculous Mycobacterial Infection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Nontuberculous Mycobacterial Infection Market Size, Comparisons And Growth Rate Analysis

7.3. Global Nontuberculous Mycobacterial Infection Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Nontuberculous Mycobacterial Infection Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nontuberculous Mycobacterial Infection Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nontuberculous Mycobacterial Infection Market Segmentation

9.1. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

9.2. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Parenteral, Other Routes Of Administration

9.3. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

9.4. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Azithromycin, Clarithromycin, Erythromycin

9.5. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy

9.6. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Amikacin, Streptomycin, Tobramycin

9.7. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Fluoroquinolones, Ethambutol, Linezolid, Clofazimine

10. Nontuberculous Mycobacterial Infection Market Regional And Country Analysis

10.1. Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nontuberculous Mycobacterial Infection Market

11.1. Asia-Pacific Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nontuberculous Mycobacterial Infection Market

12.1. China Nontuberculous Mycobacterial Infection Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nontuberculous Mycobacterial Infection Market

13.1. India Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nontuberculous Mycobacterial Infection Market

14.1. Japan Nontuberculous Mycobacterial Infection Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nontuberculous Mycobacterial Infection Market

15.1. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nontuberculous Mycobacterial Infection Market

16.1. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nontuberculous Mycobacterial Infection Market

17.1. South Korea Nontuberculous Mycobacterial Infection Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nontuberculous Mycobacterial Infection Market

18.1. Taiwan Nontuberculous Mycobacterial Infection Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nontuberculous Mycobacterial Infection Market

19.1. South East Asia Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nontuberculous Mycobacterial Infection Market

20.1. Western Europe Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nontuberculous Mycobacterial Infection Market

21.1. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nontuberculous Mycobacterial Infection Market

22.1. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nontuberculous Mycobacterial Infection Market

23.1. France Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nontuberculous Mycobacterial Infection Market

24.1. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nontuberculous Mycobacterial Infection Market

25.1. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nontuberculous Mycobacterial Infection Market

26.1. Eastern Europe Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nontuberculous Mycobacterial Infection Market

27.1. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nontuberculous Mycobacterial Infection Market

28.1. North America Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nontuberculous Mycobacterial Infection Market

29.1. USA Nontuberculous Mycobacterial Infection Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nontuberculous Mycobacterial Infection Market

30.1. Canada Nontuberculous Mycobacterial Infection Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nontuberculous Mycobacterial Infection Market

31.1. South America Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nontuberculous Mycobacterial Infection Market

32.1. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nontuberculous Mycobacterial Infection Market

33.1. Middle East Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nontuberculous Mycobacterial Infection Market

34.1. Africa Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nontuberculous Mycobacterial Infection Market Regulatory and Investment Landscape

36. Nontuberculous Mycobacterial Infection Market Competitive Landscape And Company Profiles

36.1. Nontuberculous Mycobacterial Infection Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Nontuberculous Mycobacterial Infection Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Nontuberculous Mycobacterial Infection Market Company Profiles

36.3.1. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Insmed Incorporated Overview, Products and Services, Strategy and Financial Analysis

37. Nontuberculous Mycobacterial Infection Market Other Major And Innovative Companies

Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG

38. Global Nontuberculous Mycobacterial Infection Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market

40. Nontuberculous Mycobacterial Infection Market High Potential Countries, Segments and Strategies

40.1 Nontuberculous Mycobacterial Infection Market In 2030 - Countries Offering Most New Opportunities

40.2 Nontuberculous Mycobacterial Infection Market In 2030 - Segments Offering Most New Opportunities

40.3 Nontuberculous Mycobacterial Infection Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Nontuberculous Mycobacterial Infection Market, Overview Of Key Products - Product Examples
  • Table 2: Global Nontuberculous Mycobacterial Infection Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Nontuberculous Mycobacterial Infection Market, Supply Chain Analysis
  • Table 4: Global Nontuberculous Mycobacterial Infection Market, Major Raw Material Providers
  • Table 5: Global Nontuberculous Mycobacterial Infection Market, Major Resource Providers
  • Table 6: Global Nontuberculous Mycobacterial Infection Market, Major Manufacturers (Suppliers)
  • Table 7: Global Nontuberculous Mycobacterial Infection Market, Major Distributors And Channel Partners
  • Table 8: Global Nontuberculous Mycobacterial Infection Market, Key Technologies & Future Trends
  • Table 9: Global Nontuberculous Mycobacterial Infection Market, Major Trends
  • Table 10: Global Nontuberculous Mycobacterial Infection Market, Major End Users
  • Table 11: Global Nontuberculous Mycobacterial Infection Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Nontuberculous Mycobacterial Infection Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Nontuberculous Mycobacterial Infection Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Nontuberculous Mycobacterial Infection Market - TAM, US$ Billion, 2025
  • Table 15: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Global Nontuberculous Mycobacterial Infection Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 97: Global Nontuberculous Mycobacterial Infection Market - Company Scoring Matrix
  • Table 98: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Table 99: Mylan N.V. Financial Performance
  • Table 100: Sun Pharmaceutical Industries Ltd. Financial Performance
  • Table 101: Lupin Limited Financial Performance
  • Table 102: Insmed Incorporated Financial Performance
  • Table 103: Global Nontuberculous Mycobacterial Infection Market, Competitive Benchmarking (In USD Billions)
  • Table 104: Global Nontuberculous Mycobacterial Infection Market, Competitive Dashboard
  • Table 105: Global Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 106: Global, Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Table 107: Global, Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Table 108: Global, Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Nontuberculous Mycobacterial Infection Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Nontuberculous Mycobacterial Infection Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Nontuberculous Mycobacterial Infection Market, Supply Chain Analysis
  • Figure 4: Global Nontuberculous Mycobacterial Infection Market, Major Raw Material Providers
  • Figure 5: Global Nontuberculous Mycobacterial Infection Market, Major Resource Providers
  • Figure 6: Global Nontuberculous Mycobacterial Infection Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Nontuberculous Mycobacterial Infection Market, Major Distributors And Channel Partners
  • Figure 8: Global Nontuberculous Mycobacterial Infection Market, Key Technologies & Future Trends
  • Figure 9: Global Nontuberculous Mycobacterial Infection Market, Major Trends
  • Figure 10: Global Nontuberculous Mycobacterial Infection Market, Major End Users
  • Figure 11: Global Nontuberculous Mycobacterial Infection Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Nontuberculous Mycobacterial Infection Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Nontuberculous Mycobacterial Infection Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Nontuberculous Mycobacterial Infection Market - TAM, US$ Billion, 2025
  • Figure 15: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Global Nontuberculous Mycobacterial Infection Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 97: Global Nontuberculous Mycobacterial Infection Market - Company Scoring Matrix
  • Figure 98: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Figure 99: Mylan N.V. Financial Performance
  • Figure 100: Sun Pharmaceutical Industries Ltd. Financial Performance
  • Figure 101: Lupin Limited Financial Performance
  • Figure 102: Insmed Incorporated Financial Performance
  • Figure 103: Global Nontuberculous Mycobacterial Infection Market, Competitive Benchmarking (In USD Billions)
  • Figure 104: Global Nontuberculous Mycobacterial Infection Market, Competitive Dashboard
  • Figure 105: Global Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 106: Global, Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Figure 107: Global, Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Figure 108: Global, Nontuberculous Mycobacterial Infection Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Nontuberculous Mycobacterial Infection Market Report 2026 - Global Outlook – By Drug Class (Macrolides, Rifampin, Aminoglycoside, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Other Routes Of Adminis...

Tuberculosis Diagnostics Market Report 2026 - Global Outlook – By Test Type (Radiographic Tests, Nucleic Acid Testing, Cytokine Detection Tests, Drug Resistance Tests, Skin Test / Mantoux Test (TST), Blood/Serology Test,...

Clinical Microbiology Market Report 2026 - Global Outlook – By Product (Laboratory Instruments, Microbiology Analyzers, Reagents), By Indication (Respiratory Diseases, Sexually Transmitted Diseases, Urinary Tract Infecti...

Rare Disease Diagnostics Market Report 2026 - Global Outlook – By Test Type (Genetic Test, General Lab Test, Imaging Test), By Technology (Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarray...

Interstitial Cystitis Market Report 2026 - Global Outlook – By Treatment (Medications, Bladder Instillation, Botulinum Toxin A, Nerve Stimulation, Surgery), By Patient Type (Pediatric Patients, Adult Patients), By Drug T...

Bactericide Market Report 2026 - Global Outlook – By Type (Organic Bactericides, Inorganic Bactericides, Biological Bactericides), By Formulation Type (Liquid Bactericides, Granular Bactericides, Powdered Bactericides), ...

Bacterial Conjunctivitis Market Report 2026 - Global Outlook – By Type (Hyperacute Bacterial Conjunctivitis, Acute Bacterial Conjunctivitis, Chronic Bacterial Conjunctivitis), By Drug Class (Antibiotics, Fluoroquinolones...

Hospital-Acquired Infection Control Market Report 2026 - Global Outlook – By Product (Sterilizers, Disinfectors, Endoscope Reprocessors, Microbial Testing Instruments, Consumables, Disinfectants, Infection Prevention And...

Frequently Asked Questions

The Nontuberculous Mycobacterial Infection market was valued at $14.96 billion in 2025, increased to $15.87 billion in 2026, and is projected to reach $21.01 billion by 2030.

The global Nontuberculous Mycobacterial Infection market is expected to grow at a CAGR of 7.3% from 2026 to 2035 to reach $21.01 billion by 2035.

Some Key Players in the Nontuberculous Mycobacterial Infection market Include, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd. .

Major trend in this market includes: Innovations In Boron-Based Antibiotics Enhance Treatment Efficacy And Address Drug-Resistant Nontuberculous Mycobacterial Infections. For further insights on this market. request a sample here

North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the nontuberculous mycobacterial infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us